Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology companies in Europe. The development of fundamentally novel, cutting-edge biopharmaceuticals for treatment of many diseases with high medical need drives our success.
We are committed to serving patient needs by making medicine truly personal. Our vision is to offer precisely targeted, highly effective, and well-tolerated therapies – innovative medicines as unique as you!
BioNtech Diagnostics launches the new IVD MammaTyper® Kit in 2015. MammaTyper® is a molecular in vitro diagnostics test kit delivering a precise and reproducible biomarker analysis which allows subsequent classification of breast cancer tumors. The test allows the quantitative detection of the mRNA expression status of estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki-67 derived from FFPE tissue. In a unique way MammaTyper® combines breast cancer diagnostics with additional information about prognosis and prediction for systemic therapy.
RNXtract® RNA Extraction Kit offers a reliable and well-proven method to gain highly purified total RNA from formalin-fixed, paraffin-embedded (FFPE) tissue.
An der Goldgrube 12
D-55131 Mainz, Germany